Last10K.com

21St Century Oncology Holdings, Inc. (RTSX) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2013

21St Century Oncology Holdings, Inc.

CIK: 1503518 Ticker: RTSX

Exhibit 99.1

 

 

21ST CENTURY ONCOLOGY HOLDINGS, INC.

 

Contact:

Bryan J. Carey

President and CFO

239-931-7285

BCarey@rtsx.com

 

Investors:

Nick Laudico

The Ruth Group

646-536-7030

nlaudico@theruthgroup.com

 

21ST CENTURY ONCOLOGY REPORTS FOURTH QUARTER AND FULL YEAR 2013 FINANCIAL RESULTS

 

Fourth Quarter 2013 Highlights:

 

·                  Total company pro forma revenues of $209.2 million, up 23.9% year-over-year, including $5.8 million in pro forma contribution from acquisitions; excluding acquisitions, revenues grew 20.5% year-over-year

·                  Total domestic Radiation Oncology cases completed increased 12.3%

·                  Domestic same market treatments per day increased 7.9%

·                  International cases increased 7.0%

·                  Pro Forma Adjusted EBITDA of $27.2 million

·                  Completed acquisition of OnCure Holdings, Inc. (“Oncure”) on October 25, adding significant scale and opportunity for long term revenue growth and operating synergies

·                  Transitioned corporate identity to 21st Century Oncology brand, recognized globally for high quality integrated cancer care (“ICC”) services

·                  Acquired strategically located radiation therapy facility with certificate of need (“CON”) in Roanoke Rapids, NC; upgrading with advanced technologies and clinical pathways

·                  Entered strategic partnership with ProHealth Care Associates, LLP, the largest physician group practice in the metropolitan New York area, to operate an ICC  practice in Riverhead, NY as well as jointly pursue additional strategic opportunities

 

Full Year 2013 Highlights:

 

·                  Total company pro forma revenues of $845.3 million, up 20.7% year-over-year, including $108.8 million in pro forma contribution from acquisitions; excluding acquisitions, revenues grew 6.1% year-over-year

·                  Total domestic Radiation Oncology cases completed increased 13.1%

·                  Domestic same market treatments per day increased 4.3%

·                  International cases increased 5.7%

·                  Pro Forma Adjusted EBITDA of $118.6 million

 

FORT MYERS, FL, February, 19, 2014 — 21

st Century Oncology Holdings, Inc. (“21st Century Oncology”, “21C” or the “Company”), the leading global, physician-led provider of

 


The following information was filed by 21St Century Oncology Holdings, Inc. (RTSX) on Wednesday, February 19, 2014 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate 21St Century Oncology Holdings, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by 21St Century Oncology Holdings, Inc..

Continue

Assess how 21St Century Oncology Holdings, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

21St Century Oncology Holdings, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2014 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Cash Flows (parenthetical)
Consolidated Statements Of Changes In Equity
Consolidated Statements Of Operations And Comprehensive Loss
Accrued Expenses
Accrued Expenses (details)
Accrued Expenses (tables)
Acquisitions And Other Arrangements
Acquisitions And Other Arrangements (narrative) (details)
Acquisitions And Other Arrangements (schedule Of Estimated Future Amortization Expense For The Acquired Amortizable Intangible Assets 2) (details)
Acquisitions And Other Arrangements (schedule Of Estimated Future Amortization Expense For The Acquired Amortizable Intangible Assets) (details)
Acquisitions And Other Arrangements (schedule Of Preliminary Intangible Assets Included In Net Identifiable Assets) (details)
Acquisitions And Other Arrangements (schedule Of The Allocation Of The Purchase Price) (details)
Acquisitions And Other Arrangements (schedule Of Unaudited Pro Forma Financial Information) (details)
Acquisitions And Other Arrangements (summary Of Allocation Of The Aggregate Purchase Price, Including Assumed Liabilities) (details)
Acquisitions And Other Arrangements (tables)
Capital Lease Arrangements
Capital Lease Arrangements (details)
Capital Lease Arrangements (tables)
Commitments And Contingencies
Commitments And Contingencies (future Minimum Annual Lease Commitments) (details)
Commitments And Contingencies (narrative) (details)
Commitments And Contingencies (outstanding Letters Of Credit) (details)
Commitments And Contingencies (tables)
Equity Investments In Joint Ventures
Equity Investments In Joint Ventures (details)
Equity Investments In Joint Ventures (schedule Of The Condensed Financial Position) (details)
Equity Investments In Joint Ventures (schedule Of The Condensed Results Of Operations) (details)
Equity Investments In Joint Ventures (summary Of The Changes In The Equity Investment In The Unconsolidated Joint Ventures) (details)
Equity Investments In Joint Ventures (tables)
Fair Value Of Financial Instruments
Fair Value Of Financial Instruments (narrative) (details)
Fair Value Of Financial Instruments (schedule Of Fair Value Debt Instruments Based On Level 2) (details)
Fair Value Of Financial Instruments (schedule Of Items Measured At Fair Value On Recurring Basis) (details)
Fair Value Of Financial Instruments (tables)
Goodwill And Intangible Assets
Goodwill And Intangible Assets (narrative) (details)
Goodwill And Intangible Assets (schedule Of Accumulated Impairment Losses) (details)
Goodwill And Intangible Assets (schedule Of Changes In The Carrying Amount Of Goodwill) (details)
Goodwill And Intangible Assets (schedule Of Components Of Intangible Assets) (details)
Goodwill And Intangible Assets (schedule Of Estimated Future Amortization Expense) (details)
Goodwill And Intangible Assets (summary Of Impairment Charges Relating To Goodwill And Trade Name) (details)
Goodwill And Intangible Assets (tables)
Income Taxes
Income Taxes (narrative) (details)
Income Taxes (reconciliation Of Statutory Tax Rate To Effective Tax Rate) (details)
Income Taxes (schedule Of Deferred Tax Assets And Liabilities) (details)
Income Taxes (schedule Of Reconciliation Of Gross Unrecognized Tax Benefits) (details)
Income Taxes (schedule Of Significant Components Of Income Tax Provision) (details)
Income Taxes (schedule Of Valuation Allowance) (details)
Income Taxes (tables)
Liquidity
Liquidity (details)
Long-term Debt
Long-term Debt (amended And Restated Credit Agreement) (details)
Long-term Debt (details)
Long-term Debt (schedule Of Company's Long-term Debt) (details)
Long-term Debt (schedule Of Financial Covenants Compliance Under The Revolving Credit Facility) (details)
Long-term Debt (schedule Of Maturities Of Long-term Debt Obligations) (details)
Long-term Debt (senior Secured Second Lien Notes) (details)
Long-term Debt (senior Subordinated Notes) (details)
Long-term Debt (tables)
Organization And Basis Of Presentation
Organization And Basis Of Presentation (details)
Other Income And Loss
Other Income And Loss (additional Information) (details)
Other Income And Loss (early Extinguishment Of Debt) (details)
Other Income And Loss (impairment Loss) (details)
Other Income And Loss (loss On Investments And Ehr Incentives) (details)
Property And Equipment
Property And Equipment (details)
Property And Equipment (tables)
Real Estate Subject To Finance Obligation
Real Estate Subject To Finance Obligation (narrative) (details)
Real Estate Subject To Finance Obligation (schedule Of Future Payments Of The Finance Obligation) (details)
Real Estate Subject To Finance Obligation (schedule Of Net Book Values Of Real Estate Subject To Finance Obligation) (details)
Real Estate Subject To Finance Obligation (tables)
Reconciliation Of Total Equity And Noncontrolling Interests
Reconciliation Of Total Equity And Noncontrolling Interests (details)
Reconciliation Of Total Equity And Noncontrolling Interests (tables)
Related Party Transactions (details)
Related-party Transactions
Retirement And Deferred Compensation Plans
Retirement And Deferred Compensation Plans (details)
Segment And Geographic Information
Segment And Geographic Information (narrative) (details)
Segment And Geographic Information (schedule Of Financial Information By Geographic Segment) (details)
Segment And Geographic Information (schedule Of Reconciliation Of The Company's Reportable Segment Profit And Loss) (details)
Segment And Geographic Information (tables)
Stock Option Plan And Restricted Stock Grants
Stock Option Plan And Restricted Stock Grants (narrative) (details)
Stock Option Plan And Restricted Stock Grants (summary Of Units Activity Under The Plan) (details)
Stock Option Plan And Restricted Stock Grants (tables)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (narrative) (details)
Summary Of Significant Accounting Policies (policy)
Summary Of Significant Accounting Policies (schedule Of Antidilutive Shares) (details)
Summary Of Significant Accounting Policies (schedule Of Components Of Accumulated Other Comprehensive Loss) (details)
Summary Of Significant Accounting Policies (schedule Of Current Foreign Currency Derivative Agreements) (details)
Summary Of Significant Accounting Policies (schedule Of Inventories) (details)
Summary Of Significant Accounting Policies (schedule Of Major Asset Classifications And Useful Lives) (details)
Summary Of Significant Accounting Policies (summary Of The Activity In The Allowance For Doubtful Accounts) (details)
Summary Of Significant Accounting Policies (tables)
Supplemental Consolidating Financial Information
Supplemental Consolidating Financial Information (narrative) (details)
Supplemental Consolidating Financial Information (schedule Of Consolidating Balance Sheet) (details)
Supplemental Consolidating Financial Information (schedule Of Consolidating Statement Of Cash Flows) (details)
Supplemental Consolidating Financial Information (schedule Of Consolidating Statements Of Operations And Comprehensive Income (loss)) (details)
Supplemental Consolidating Financial Information (tables)
Unaudited Quarterly Financial Information
Unaudited Quarterly Financial Information (details)
Unaudited Quarterly Financial Information (tables)
Ticker: RTSX
CIK: 1503518
Form Type: 10-K Annual Report
Accession Number: 0001047469-14-004488
Submitted to the SEC: Thu May 01 2014 8:53:47 AM EST
Accepted by the SEC: Thu May 01 2014
Period: Tuesday, December 31, 2013
Industry: Offices And Clinics Of Doctors Of Medicine

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/rtsx/0001047469-14-004488.htm